Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.45 |
| ▸ | PPARD | Q03181 | 6/20 | 0.45 |
| ▸ | PPARG | P37231 | 5/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30485736 | 0.86 | MAOB (0.46) | MAP3K14FFAR1PPARDPPARGMAOB | |
| SCHEMBL21056035 | 0.86 | MAOB (0.46) | MAP3K14FFAR1PPARDPPARGMAOB | |
| SCHEMBL4705434 | 0.83 | MAP3K14 (0.46) | MAP3K14FFAR1PPARDPPARGMAOB | |
| SCHEMBL17361476 | 0.79 | FFAR1 (0.45) | FFAR1PPARDPPARGKDM4CCA2 | |
| SCHEMBL6100820 | 0.79 | PPARD (0.40) | FFAR1PPARDPPARGKDM4CCA2 | |
| SCHEMBL12362004 | 0.79 | FFAR1 (0.47) | FFAR1PPARDPPARGCA2 | |
| SCHEMBL4704564 | 0.78 | CA2 (0.42) | MAP3K14FFAR1PPARDPPARGMAOB | |
| SCHEMBL12533501 | 0.77 | MAP3K14 (0.69) | MAP3K14FFAR1PPARDPPARGCA2 | |
| SCHEMBL2317457 | 0.76 | CYP3A4 (0.51) | FFAR1PPARDPPARGDRD2DRD3 | |
| SCHEMBL2317460 | 0.76 | CYP3A4 (0.51) | FFAR1PPARDPPARGDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567489-B1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20060166985-A1 | Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa | GLAXO GROUP LIMITED (GB) | 2006-07-27 | — | — | US | disclosed |
| EP-1567489-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004052851-A1 | PYRROLYDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA | GLAXO GROUP LIMITED (GB) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166985-A1 | Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa | TFPI, TFPI2, SERPINC1 | MAP3K14 2347/4885FFAR1 4730/4885PPARD 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.